All the news Showing 10 of 32 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Advent of DAAs accompanied by dramatic improvement in survival after HCV-related liver transplant Michael Carter / 18 July 2018 Survival among people with hepatitis C virus (HCV) undergoing liver transplant has improved significantly since the introduction of direct-acting antivirals (DAAs), investigators from Catalonia report in the Journal of Hepatology. Thanks to DAAs, there ... Direct-acting antivirals bring fewer HCV-related liver transplants, better survival after transplantation, in Europe Michael Carter / 16 April 2018 There has been a steep fall in the number of hepatitis C virus (HCV)-related liver transplants since the introduction of direct-acting antivirals (DAAs), according to European research presented to the ... HCV treatment allows one in four people to come off the transplant waiting list Keith Alcorn / 24 April 2017 Around one in four people with hepatitis C and decompensated cirrhosis came off the transplant waiting list in Europe after direct-acting antiviral treatment, and very few had any subsequent liver-related ... DAA therapy cures most people with HIV/HCV co-infection with decompensated cirrhosis or liver transplants Liz Highleyman / 07 March 2017 People with HIV/hepatitis C virus (HCV) co-infection with liver cirrhosis or liver failure, and those who received liver transplants, saw high rates of sustained virological response using interferon-free direct-acting antiviral (DAA) therapy for ... Is DAA treatment for hepatitis C reducing the need for liver transplants? Liz Highleyman / 25 January 2017 People successfully treated for hepatitis are less likely to need liver transplants and less likely to die while on a transplant waiting list, according to studies presented at the 2016 ... EASL issues new hepatitis C treatment recommendations for all genotypes Liz Highleyman / 26 September 2016 The European Association for the Study of the Liver (EASL) released its latest recommendations on treatment of hepatitis C at a special meeting last Thursday in Paris. The updated guidelines now include highly ... Improvements in HIV treatment and care have had no impact on rates of endstage liver disease among HIV-positive people with viral hepatitis Michael Carter / 01 September 2016 Incidence of endstage liver disease (ESLD) among HIV-positive people with viral hepatitis changed little between 1996 and 2010, despite major improvements in HIV treatment and care, investigators from Canada and the United States ... Hepatitis C treatment may not be enough to stop the progress of advanced liver disease, or reduce liver transplant need Keith Alcorn / 14 April 2016 Doctors need to have “full and frank” discussions with patients about the potential risks and benefits of using direct-acting antivirals to treat hepatitis C in late-stage liver disease, especially among those waiting for ... Daclatasvir approved for use in HIV/HCV co-infection, decompensated cirrhosis and post-transplant in the EU Keith Alcorn / 03 February 2016 The hepatitis C direct-acting antiviral daclatasvir (Daklinza) has received European Union marketing approval for use in three new populations of people with genotype 1, 3 or 4 hepatitis C infection. The NS5A inhibitor ... Clinical impact of effective HCV DAAs: referrals for liver transplant drop after their introduction Keith Alcorn / 04 December 2015 The number of hepatitis C virus (HCV)-related referrals for liver transplant has declined significantly since the introduction of HCV direct-acting antivirals (DAAs), according to two US studies presented to the recent 2015 ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive